DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Gastrointestinal and Other Cancers
National Cancer Institute (NCI)
Active, not recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT02772003
This phase I trial studies the side effects and best dose of deoxyribonucleic acid (DNA) vaccine therapy in treating patients with hepatitis C virus (HCV) infection that persists or progresses over a long period of time. Vaccines made from DNA may help the body build an effective immune response to kill cancer cells that express HCV infection.
Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rocakinogene Sifuplasmid
Chronic Hepatitis, Hepatitis C Infection
Jeffrey M Jacobson

See list of participating sites